PIDD
Showing 1 - 22 of 22
Primary Immunodeficiency Diseases (PID) Trial (TAK-881, HYQVIA)
Not yet recruiting
- Primary Immunodeficiency Diseases (PID)
- TAK-881
- HYQVIA
- (no location specified)
Feb 23, 2023
Primary Immune Deficiency Trial (Asceniv™)
Recruiting
- Primary Immune Deficiency
- Asceniv™
-
Centennial, Colorado
- +2 more
Sep 13, 2022
Primary Immunodeficiency Diseases (PID) Trial (TAK-881)
Not yet recruiting
- Primary Immunodeficiency Diseases (PID)
- TAK-881
- (no location specified)
Oct 4, 2023
COVID-19 Vaccine Responses in PIDD Subjects
Recruiting
- X-linked Agammaglobulinemia
- +6 more
-
Saint Petersburg, Florida
- +2 more
Apr 7, 2022
Primary Immune Deficiency Disorders (PIDD) Trial in United States (Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%])
Completed
- Primary Immune Deficiency Disorders (PIDD)
- Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]
-
Birmingham, Alabama
- +16 more
Jul 28, 2021
Primary Immunodeficiency Diseases (PID) Trial in United States (Immune Globulin Infusion (Human), 10%, Recombinant human
Completed
- Primary Immunodeficiency Diseases (PID)
- Immune Globulin Infusion (Human), 10%
- Recombinant human hyaluronidase
-
Irvine, California
- +9 more
Apr 30, 2021
Primary Immunodeficiency Diseases (PID) Trial in United States (HYQVIA, GAMMAGARD LIQUID)
Completed
- Primary Immunodeficiency Diseases (PID)
- HYQVIA
- GAMMAGARD LIQUID
-
Birmingham, Alabama
- +18 more
Sep 28, 2022
Primary Immunodeficiency Diseases (PID) Trial in Canada, United States (Immune Globulin Intravenous (Human), 10% Solution,
Completed
- Primary Immunodeficiency Diseases (PID)
- Immune Globulin Intravenous (Human), 10% Solution
- Immune Globulin Subcutaneous (Human), 20% Solution
-
Irvine, California
- +17 more
Jun 30, 2021
Intestinal Inflammation in People With Primary Immune
Recruiting
- Chronic Granulomatous Disease
- Inflammatory Bowel Disease
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Primary Immune Deficiency Diseases (PIDD) Trial in Canada, United States (10% IGIV)
Unknown status
- Primary Immune Deficiency Diseases (PIDD)
- 10% IGIV
-
Los Angeles, California
- +11 more
May 6, 2020
5% Treatment Naïve Intravenous Immunoglobulin Primary
Completed
- Primary Immunodeficiency Disease (PIDD)
-
Newport Beach, California
- +3 more
Aug 6, 2019
Primary Immunodeficiency Trial in United States (Immune Globulin Intravenous, Prometic's Immune Globulin Intravenous 10%)
Completed
- Primary Immunodeficiency
- Immune Globulin Intravenous
- Prometic's Immune Globulin Intravenous 10%
-
Irvine, California
- +12 more
Nov 3, 2021
Participation in a Research Registry for Immune Disorders
Recruiting
- Primary Immunodeficiencies
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Apr 7, 2022
Refractory Viral Infections Trial in Washington (mCTLs)
Completed
- Refractory Viral Infections
- mCTLs
-
Washington, District of ColumbiaChildrens National Medical Center
Jan 15, 2020
Database for Primary Immunodeficiency Disease (GOOD-SHEPARD-PI)
Terminated
- Primary Immune Deficiency Disorder
- Immunoglobulin Therapy
-
Lenexa, KansasBriovaRx Infusion Services
Aug 5, 2019
Primary Immune Deficiency Disorder Trial in Kuwait
Completed
- Primary Immune Deficiency Disorder
-
Kuwait, KuwaitPediatric Deprtmemt, Alsabah hospital
Sep 5, 2019
Octagam 5% Versus Comparator Post Marketing Trial
Completed
- Primary Immune Deficiency Disorder
- Octagam 5%
- Other marketed IVIG product
-
Granada Hills, California
- +26 more
Jun 7, 2019
Asthma Trial in London (Self management education)
Completed
- Asthma
- Self management education
-
London, United KingdomNHLI at Charing Cross Hospital Campus
Jan 17, 2020
Primary Immune Deficiency Disorder Trial in United States (RI-002)
Completed
- Primary Immune Deficiency Disorder
- RI-002
-
Cenntennial, Colorado
- +8 more
Aug 10, 2016
Construction ofHealth-related Quality of Life Questionnaire for
Completed
- Immune Deficiency, Antibody
- questionnaire survey
- (no location specified)
Jan 12, 2017
Primary Immune Deficiency Diseases Trial in St. Petersburg (Bacteriophage OX174)
Unknown status
- Primary Immune Deficiency Diseases
- Bacteriophage OX174
-
St. Petersburg, FloridaUniversity of South Florida
Jul 16, 2012
Primary Immunodeficiency Disorders Trial in St. Petersburg (Hizentra)
Unknown status
- Primary Immunodeficiency Disorders
-
St. Petersburg, FloridaUniversity of South Florida
Jul 16, 2012